Assays for Follicle Stimulating Hormone and Luteinising Hormone: Guidelines for the Provision of a Clinical Biochemistry Service

Annals of Clinical Biochemistry - Tập 24 Số 3 - Trang 246-262 - 1987
G.H. Beastall, K M Ferguson1, Denis St J O’Reilly, Surajit Gorai2, B. Sheridan3
1Department of Biochemical Endocrinology, Chelsea Hospital for Women, Dovehouse Street, London SW3 6LT
2Immunoassay Section, Department of Clinical Chemistry, 12 Bristo Place, Edinburgh EH1 1ED
3Endocrine Laboratory, Royal Victoria Hospital, Belfast BT12 6BA, UK

Tóm tắt

The measurement of serum follicle stimulating hormone (FSH) and luteinising hormone (LH), together with the appropriate sex steroid, is of great value in the investigation of delayed and precocious puberty, hypogonadism, subfertility, polycystic ovarian disease and hypothalamic-pituitary disorders. Dynamic function testing of the hypothalamic-pituitary-gonadal axis should be restricted to a few defined situations. Sequential LH measurements, either in serum or in urine, may be used to time ovulation during artificial insemination or in vitro fertilisation programmes. No special precautions are necessary when sampling for FSH and LH measurement; serum is preferred to plasma and should be stored frozen before assay. Aliquots of timed urine specimens of known volume should be stored frozen without preservative. Gonadotropin results should be available within 2–3 weeks; laboratories unable to meet this schedule are advised to send their samples to a Regional Centre for assay. Reagents for the radioimmunoassay of FSH and LH are readily available, and standard techniques have been developed for their use. Laboratories using ‘in-house’ methods should pay particular attention to the matrix used for preparing standard solutions, the purification of radioligands and the optimisation of the separation system. Low cost matched reagents of proven performance are available in kit form from the Chelsea Hospital for Women; several commercial kits are also available, although few are widely used in the UK. The overall performance of laboratories in the UK External Quality Assessment Scheme (EQAS) for FSH and LH has remained steady for several years. Of the 130 participants, only about 15% in each scheme have ‘good’ performance (cumulative bias less than 10%, plus cumulative variability of bias less than 10%), whilst a similar proportion have ‘unacceptable’ performance (cumulative bias greater than 20% and/or cumulative variability of bias greater than 25%). The remaining 70% of laboratories have ‘adequate’ performance but are at risk of producing results that are clinically misleading. Within any one method group, the performance of FSH and LH assays are closely related. Optimal assay performance depends upon sensible laboratory management to ensure skilled operators, a regular programme of reagent/kit renewal, comprehensive internal and external quality assessment, and attention to detail in all aspects of gonadotrophin assay. The working range of each individual assay should be defined and no absolute result reported from outside this range. Mean intra-assay and interassay coefficients of variation on selected human serum quality control pools should be better than 8% and 15%, respectively, for both gonadotrophins. All laboratories performing FSH and LH assays should belong to the UK EQAS for gonadotrophins. Immunometric assays, using monoclonal antibodies, will supersede radioimmunoassays for FSH and LH during the next few years. Some of these assays will have non-isotopic labels.

Từ khóa


Tài liệu tham khảo

10.1210/endo-98-6-1554

Clayton RN, 1984, Quart J Med, 53, 17

Yen SSC, 1986, Reproductive Endocrinology: Physiology, Pathophysiology and Clinical Management., 2

Ismail AAA, 1981, Biochemical Investigations in Endocrinology.

10.1016/S0300-595X(82)80038-8

10.1177/000456328602300201

10.1056/NEJM198501103120201

10.1210/edrv-6-4-552

10.1056/NEJM196712282772604

10.1136/bmj.284.6330.1681

Lachelin G., 1984, Progress in Obstetrics and Gynaecology, 4, 290

Shaw RW, 1976, Clinics Obs Gynaecol, 3, 485, 10.1016/S0306-3356(21)00360-5

10.1111/j.1365-2265.1981.tb00639.x

10.1210/edrv-5-1-62

10.1016/S0009-9120(80)91040-1

10.1093/clinchem/28.1.164

10.1530/acta.0.1010339

Henly R, 1980, Med Lab Sci, 37, 367

10.1177/000456328201900507

Ferguson KM, 1983, Immunoassay for Clinical Chemistry., 289

Brown NS, 1983, Immunoassay for Clinical Chemistry., 267

10.1016/0003-2697(75)90266-3

Salacinski P, 1979, J Endocrinol, 81, 131P, 10.1677/joe.0.0810131

10.1177/000456328201900214

Bolton AE, 1976, Protides of the Biological Fluids—Proc. 24th Colloquium, Brugge., 187

10.1530/acta.0.0890506

Edwards R, 1983, Immunoassay for Clinical Chemistry., 277

10.1093/oxfordjournals.bmb.a071161

10.1177/000456328402100408

Court G, 1971, Radioimmunoassay Methods., 283

Edwards R., 1983, Immunoassay for Clinical Chemistry., 139

10.1530/acta.0.0810043

Forrest GC, 1983, Immunoassay for Clinical Chemistry., 147

Wright JF, 1983, Immunoassay for Clinical Chemistry., 170

Sutherland RM, 1983, Immunoassay for Clinical Chemistry., 128

Ekiuns RP, 1983, Immunoassay for Clinical Chemistry., 76

10.1677/joe.0.0800059

Jeffcoate SL, 1981, Efficiency and Effectiveness in the Endocrine Laboratory.

10.1177/000456328502200101

Finney DJ, 1983, Immunoassay for Clinical Chemistry., 591

10.1177/000456327701400170

10.1093/clinchem/25.3.353

10.1177/000456328001700501

10.1177/000456328502200214

10.1093/oxfordjournals.bmb.a071166

Hunter WM, 1982, Proc Roy Soc Edinburgh, 81, 293

Beastall GH, 1985, Laboratory Practice, 34, 74

10.1111/j.1365-2265.1984.tb03446.x

10.1038/305158a0

10.1016/S0140-6736(85)91053-0

Biggart EM, 1985, J Endocrinol, 104, 125

Thông tin
Thông tin xuất bản

Annals of Clinical Biochemistry

Tập 24 Số 3

246-262

Thông tin tác giả